Serkan Oral1, Sebahattin Celik2, Yasam Kemal Akpak3, Hakan Golbasi4, Burak Bayraktar3, Gokhan Unver5, Sami Sahin5, Nazan Yurtcu6, Canan Soyer Caliskan5. 1. Department of Obstetrics and Gynaecology, Halic University, Istanbul, Turkey. 2. Department of Obstetrics and Gynecology, Balikesir State Hospital, Balikesir, Turkey. 3. Department of Obstetrics and Gynecology, University of Health Sciences Tepecik Training and Research Hospital, Izmir, Turkey. 4. Department of Perinatology, Bakırcay University Cigli Education and Research Hospital, Izmir, Turkey. drhkngolbasi@gmail.com. 5. Department of Obstetrics and Gynecology, University of Health Sciences Samsun Training and Research Hospital, Samsun, Turkey. 6. Department of Obstetrics and Gynecology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey.
Abstract
PURPOSE: Zonulin has been shown to be associated with many metabolic disorders, including type 2 diabetes mellitus, metabolic syndrome, and obesity. In this study, we aimed to evaluate the association between maternal plasma zonulin levels and gestational diabetes mellitus (GDM) and its perinatal outcomes. MATERIALS: A total of 100 pregnant women, 56 with GDM and 44 controls, were included in this prospective case-control study. Maternal plasma zonulin levels were evaluated in each trimester. The association between zonulin levels and GDM, body mass index (BMI) and adverse perinatal outcomes was evaluated. The GDM predictability of zonulin levels for each trimester was analyzed with the receiver operator curve (ROC). RESULTS: Plasma zonulin levels were significantly higher in pregnant with GDM in all trimesters (p < 0.001; for all). Optimum cut-off values of plasma zonulin levels in predicting GDM: first trimester: 6.27 ng/mL, second trimester: 12.71 ng/mL, and third trimester: 18.38 ng/mL. BMI was significantly higher in pregnant women with GDM (30.5 vs 26.1; p < 0.001). Zonulin levels were significantly higher in pregnant women with GDM with overweight BMI [≥ 25-30 (kg/m2)] in all trimesters (p < 0.05; for all). Zonulin levels were significantly higher in pregnant women with composite adverse outcomes that included at least one of neonatal intensive care unit (NICU) admission, meconium-stained amniotic fluid, and 1st minute APGAR score < 7. CONCLUSION: Increased maternal plasma zonulin levels were associated with increased risk of GDM and adverse perinatal outcomes. Zonulin may be a potential marker to predict GDM risk and perinatal outcomes.
PURPOSE: Zonulin has been shown to be associated with many metabolic disorders, including type 2 diabetes mellitus, metabolic syndrome, and obesity. In this study, we aimed to evaluate the association between maternal plasma zonulin levels and gestational diabetes mellitus (GDM) and its perinatal outcomes. MATERIALS: A total of 100 pregnant women, 56 with GDM and 44 controls, were included in this prospective case-control study. Maternal plasma zonulin levels were evaluated in each trimester. The association between zonulin levels and GDM, body mass index (BMI) and adverse perinatal outcomes was evaluated. The GDM predictability of zonulin levels for each trimester was analyzed with the receiver operator curve (ROC). RESULTS: Plasma zonulin levels were significantly higher in pregnant with GDM in all trimesters (p < 0.001; for all). Optimum cut-off values of plasma zonulin levels in predicting GDM: first trimester: 6.27 ng/mL, second trimester: 12.71 ng/mL, and third trimester: 18.38 ng/mL. BMI was significantly higher in pregnant women with GDM (30.5 vs 26.1; p < 0.001). Zonulin levels were significantly higher in pregnant women with GDM with overweight BMI [≥ 25-30 (kg/m2)] in all trimesters (p < 0.05; for all). Zonulin levels were significantly higher in pregnant women with composite adverse outcomes that included at least one of neonatal intensive care unit (NICU) admission, meconium-stained amniotic fluid, and 1st minute APGAR score < 7. CONCLUSION: Increased maternal plasma zonulin levels were associated with increased risk of GDM and adverse perinatal outcomes. Zonulin may be a potential marker to predict GDM risk and perinatal outcomes.
Authors: B Jayashree; Y S Bibin; D Prabhu; C S Shanthirani; K Gokulakrishnan; B S Lakshmi; V Mohan; M Balasubramanyam Journal: Mol Cell Biochem Date: 2013-12-18 Impact factor: 3.396
Authors: Eliana M Wendland; Maria Regina Torloni; Maicon Falavigna; Janet Trujillo; Maria Alice Dode; Maria Amélia Campos; Bruce B Duncan; Maria Inês Schmidt Journal: BMC Pregnancy Childbirth Date: 2012-03-31 Impact factor: 3.007
Authors: David A Sacks; David R Hadden; Michael Maresh; Chaicharn Deerochanawong; Alan R Dyer; Boyd E Metzger; Lynn P Lowe; Donald R Coustan; Moshe Hod; Jeremy J N Oats; Bengt Persson; Elisabeth R Trimble Journal: Diabetes Care Date: 2012-03 Impact factor: 19.112
Authors: José María Moreno-Navarrete; Mònica Sabater; Francisco Ortega; Wifredo Ricart; José Manuel Fernández-Real Journal: PLoS One Date: 2012-05-18 Impact factor: 3.240